Find Meso-2,3-Dimercaptosuccinic Acid manufacturers, exporters & distributors on PharmaCompass

PharmaCompass

Synopsis

Synopsis

ACTIVE PHARMA INGREDIENTS

0

CEP/COS

CEP/COS Certifications

0

JDMF

JDMFs Filed

0

EU WC

EU WC

0

KDMF

KDMF

0

VMF

NDC API

0

Listed Suppliers

Other Suppliers

API REF. PRICE (USD/KG)

MARKET PLACE

0

FDF

0INTERMEDIATES

FINISHED DOSAGE FORMULATIONS

0

FDA Orange Book

FDA (Orange Book)

0

Europe

Europe

0

Canada

Canada

0

Australia

Australia

0

Listed Dossiers

Listed Dossiers

0 DRUGS IN DEVELOPMENT

FDF Dossiers

DRUG PRODUCT COMPOSITIONS

REF. STANDARDS OR IMPURITIES

0

EDQM

0

USP

0

JP

0

Others

PATENTS & EXCLUSIVITIES

0

US Patents

0

US Exclusivities

0

Health Canada Patents

DIGITAL CONTENT

0

Data Compilation #PharmaFlow

0

Stock Recap #PipelineProspector

0

Weekly News Recap #Phispers

0

News #PharmaBuzz

GLOBAL SALES INFORMATION

Annual Reports

NA

Finished Drug Prices

NA

1 RELATED EXCIPIENT COMPANIES

1EXCIPIENTS BY APPLICATIONS

Chemistry

Click the arrow to open the dropdown
read-moreClick the button for full data set
Also known as: Meso-2,3-dimercaptosuccinic acid, 304-55-2, Dim-sa, Chemet, Dmsa, Meso-dimercaptosuccinic acid
Molecular Formula
C4H6O4S2
Molecular Weight
182.2  g/mol
InChI Key
ACTRVOBWPAIOHC-XIXRPRMCSA-N
FDA UNII
DX1U2629QE

Meso-2,3-Dimercaptosuccinic Acid
A mercaptodicarboxylic acid used as an antidote to heavy metal poisoning because it forms strong chelates with them.
Succimer is a Lead Chelator. The mechanism of action of succimer is as a Lead Chelating Activity.
1 2D Structure

Meso-2,3-Dimercaptosuccinic Acid

2 Identification
2.1 Computed Descriptors
2.1.1 IUPAC Name
(2S,3R)-2,3-bis(sulfanyl)butanedioic acid
2.1.2 InChI
InChI=1S/C4H6O4S2/c5-3(6)1(9)2(10)4(7)8/h1-2,9-10H,(H,5,6)(H,7,8)/t1-,2+
2.1.3 InChI Key
ACTRVOBWPAIOHC-XIXRPRMCSA-N
2.1.4 Canonical SMILES
C(C(C(=O)O)S)(C(=O)O)S
2.1.5 Isomeric SMILES
[C@@H]([C@@H](C(=O)O)S)(C(=O)O)S
2.2 Other Identifiers
2.2.1 UNII
DX1U2629QE
2.3 Synonyms
2.3.1 MeSH Synonyms

1. 2,3 Dimercaptosuccinic Acid

2. 2,3-dimercaptosuccinic Acid

3. Acid, 2,3-dimercaptosuccinic

4. Acid, Dimercaptosuccinic

5. Acid, Meso-dimercaptosuccinic

6. Butanedioic Acid, 2,3-dimercapto-, (r*,s*)-isomer

7. Chemet

8. Dimercaptosuccinate, Tin

9. Dimercaptosuccinic Acid

10. Dipotassium Salt Succimer

11. Disodium Salt Succimer

12. Dmsa

13. Meso Dimercaptosuccinic Acid

14. Meso-dimercaptosuccinic Acid

15. Monosodium Salt Succimer

16. Rhenium Salt Succimer

17. Ro 1 7977

18. Ro-1-7977

19. Ro17977

20. Succicaptal

21. Succimer Antimony Sodium Salt, (r*,s*)-isomer

22. Succimer, (r*,r*)-(+,-)-isomer

23. Succimer, Dipotassium Salt

24. Succimer, Disodium Salt

25. Succimer, Monosodium Salt

26. Succimer, Rhenium Salt

27. Succimer, Tin Salt

28. Tin Dimercaptosuccinate

29. Tin Salt Succimer

2.3.2 Depositor-Supplied Synonyms

1. Meso-2,3-dimercaptosuccinic Acid

2. 304-55-2

3. Dim-sa

4. Chemet

5. Dmsa

6. Meso-dimercaptosuccinic Acid

7. (2r,3s)-rel-2,3-dimercaptosuccinic Acid

8. Succimero

9. Succimerum

10. Butanedioic Acid, 2,3-dimercapto-, (2r,3s)-rel-

11. Dimercaptosuccinic Acid

12. Ro 1-7977

13. Dms-a

14. (r*,s*)-2,3-dimercaptobutanedioic Acid

15. Butanedioic Acid, 2,3-dimercapto-, (r*,s*)-

16. Succinic Acid, 2,3-dimercapto-, Meso-

17. Dx1u2629qe

18. Chebi:63623

19. Meso-2,3-dimercaptobernsteinsaeure

20. Meso-2,3-dimercaptosuccinic Acid;

21. (2r,3s)-2,3-disulfanylsuccinic Acid

22. Succimerum [inn-latin]

23. Succimero [inn-spanish]

24. (2r,3s)-2,3-dimercaptosuccinic Acid

25. Succimer [usan:inn:ban]

26. Hsdb 6783

27. 3-03-00-01033 (beilstein Handbook Reference)

28. Einecs 206-155-2

29. Brn 1725150

30. Unii-dx1u2629qe

31. Chemet (tn)

32. Mfcd00064799

33. Dimercaptosuccinic-acid

34. Succimer [hsdb]

35. Succimer [usan]

36. Succimer (usan/inn)

37. Succimer [inn]

38. Succimer [ii]

39. Succimer [mi]

40. Succimer [vandf]

41. (2s,3r)-2,3-bis(sulfanyl)butanedioic Acid

42. Succimer [mart.]

43. Succimer [who-dd]

44. Schembl14941

45. Spectrum1505007

46. Succimer [orange Book]

47. Chembl1201073

48. Dtxsid1023601

49. 2,3-bis-sulfanylbutanedioic Acid

50. Hy-b1768

51. Zinc3831475

52. S4692

53. Akos015892684

54. Ac-1366

55. Ccg-214189

56. Db00566

57. Ds-7410

58. Dmsa (meso-2,3-dimercaptosuccinic Acid)

59. Meso-2,3-dimercaptosuccinic Acid, ~98%

60. 2,3-dimercaptosuccinic Acid, Meso-

61. Cs-0013797

62. D1722

63. A17093

64. C07598

65. D00572

66. 304d552

67. A820382

68. Q423814

69. Q-201748

70. Brd-k88701661-001-01-1

2.4 Create Date
2005-07-19
3 Chemical and Physical Properties
Molecular Weight 182.2 g/mol
Molecular Formula C4H6O4S2
XLogP30.1
Hydrogen Bond Donor Count4
Hydrogen Bond Acceptor Count6
Rotatable Bond Count3
Exact Mass181.97075102 g/mol
Monoisotopic Mass181.97075102 g/mol
Topological Polar Surface Area76.6 Ų
Heavy Atom Count10
Formal Charge0
Complexity139
Isotope Atom Count0
Defined Atom Stereocenter Count2
Undefined Atom Stereocenter Count0
Defined Bond Stereocenter Count0
Undefined Bond Stereocenter Count0
Covalently Bonded Unit Count1
4 Drug and Medication Information
4.1 Drug Information
1 of 2  
Drug NameChemet
PubMed HealthSuccimer (By mouth)
Drug ClassesHeavy Metal Chelator
Drug LabelCHEMET (succimer) is an orally active, heavy metal chelating agent. The chemical name for succimer is meso 2, 3-dimercaptosuccinic acid (DMSA). Its empirical formula is C4H6O4S2 and molecular weight is 182.2. The meso-structural formula is:Succimer i...
Active IngredientSuccimer
Dosage FormCapsule
RouteOral
Strength100mg
Market StatusPrescription
CompanyRecordati Rare

2 of 2  
Drug NameChemet
PubMed HealthSuccimer (By mouth)
Drug ClassesHeavy Metal Chelator
Drug LabelCHEMET (succimer) is an orally active, heavy metal chelating agent. The chemical name for succimer is meso 2, 3-dimercaptosuccinic acid (DMSA). Its empirical formula is C4H6O4S2 and molecular weight is 182.2. The meso-structural formula is:Succimer i...
Active IngredientSuccimer
Dosage FormCapsule
RouteOral
Strength100mg
Market StatusPrescription
CompanyRecordati Rare

4.2 Therapeutic Uses

Antidotes; Chelating Agents

National Library of Medicine's Medical Subject Headings online file (MeSH, 1999)


No controlled clinical studies have been conducted with succimer in poisoning with other heavy metals. A limited number of patients have received succimer for mercury or arsenic poisoning. These patients showed increased urinary excretion of the heavy metal and varying degrees of symptomatic improvement. /Use NOT included in US product label/

US Natl Inst Health; DailyMed. Current Medication Information for CHEMET (succimer) capsule (May 2010). Available from, as of June 23, 2010: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?id=18210


Chemet is indicated for the treatment of lead poisoning in pediatric patients with blood lead levels above 45 ug/dL. Chemet is not indicated for prophylaxis of lead poisoning in a lead-containing environment; the use of Chemet should always be accompanied by identification and removal of the source of the lead exposure. /Use included in US product label/

US Natl Inst Health; DailyMed. Current Medication Information for CHEMET (succimer) capsule (May 2010). Available from, as of June 23, 2010: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?id=18210


Orphan Drug. Drug (Trade Name): Succimer (Chemet). Proposed Use: Prevent cystine kidney stones in patients with homozygous cystinuria who are prone to stone development; mercury intoxication. /From table/

Novak, K.M. (ed.). Drug Facts and Comparisons2008 Edition. Wolters Kluwer Health. St. Louis, Missouri 2008., p. KU-32


For more Therapeutic Uses (Complete) data for Succimer (10 total), please visit the HSDB record page.


4.3 Drug Warning

It is not known whether this drug is excreted in human milk. Because many drugs and heavy metals are excreted in human milk, nursing mothers requiring Chemet therapy should be discouraged from nursing their infants.

US Natl Inst Health; DailyMed. Current Medication Information for CHEMET (succimer) capsule (May 2010). Available from, as of June 23, 2010: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?id=18210


Elevated blood lead levels and associated symptoms may return rapidly after discontinuation of CHEMET because of redistribution of lead from bone stores to soft tissues and blood. After therapy, patients should be monitored for rebound of blood lead levels, by measuring blood lead levels at least once weekly until stable. However, the severity of lead intoxication (as measured by the initial blood lead level and the rate and degree of rebound of blood lead) should be used as a guide for more frequent blood lead monitoring.

US Natl Inst Health; DailyMed. Current Medication Information for CHEMET (succimer) capsule (May 2010). Available from, as of June 23, 2010: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?id=18210


All patients undergoing treatment should be adequately hydrated. Caution should be exercised in using Chemet therapy in patients with compromised renal function. Limited data suggests that Chemet is dialyzable, but that the lead chelates are not.

US Natl Inst Health; DailyMed. Current Medication Information for CHEMET (succimer) capsule (May 2010). Available from, as of June 23, 2010: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?id=18210


The possibility of allergic or other mucocutaneous reactions to the drug must be borne in mind on readministration (as well as during initial courses). Patients requiring repeated courses of Chemet should be monitored during each treatment course. One patient experienced recurrent mucocutaneous vesicular eruptions of increasing severity affecting the oral mucosa, the external urethral meatus and the perianal area on the third, fourth and fifth courses of the drug. The reaction resolved between courses and upon discontinuation of therapy.

US Natl Inst Health; DailyMed. Current Medication Information for CHEMET (succimer) capsule (May 2010). Available from, as of June 23, 2010: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?id=18210


For more Drug Warnings (Complete) data for Succimer (11 total), please visit the HSDB record page.


4.4 Drug Indication

For the treatment of lead poisoning in pediatric patients with blood lead levels above 45 µg/dL. May also be used to treat mercury or arsenic poisoning.


5 Pharmacology and Biochemistry
5.1 Pharmacology

Succimer is an orally active, heavy metal chelating agent. It forms water soluble chelates and, consequently, increases the urinary excretion of lead. Succimer is not to be used for prophylaxis of lead poisoning in a lead-containing environment. In addition, the use of succimer should always be accompanied by identification and removal of the source of the lead exposure.


5.2 MeSH Pharmacological Classification

Antidotes

Agents counteracting or neutralizing the action of POISONS. (See all compounds classified as Antidotes.)


Chelating Agents

Chemicals that bind to and remove ions from solutions. Many chelating agents function through the formation of COORDINATION COMPLEXES with METALS. (See all compounds classified as Chelating Agents.)


5.3 FDA Pharmacological Classification
5.3.1 Active Moiety
SUCCIMER
5.3.2 FDA UNII
DX1U2629QE
5.3.3 Pharmacological Classes
Lead Chelator [EPC]; Lead Chelating Activity [MoA]
5.4 Absorption, Distribution and Excretion

Absorption

Rapid but variable.


Route of Elimination

Unabsorbed drug is excreted primarily in feces and absorbed drug is excreted primarily in the urine as metabolites.


In a study performed in healthy adult volunteers, after a single dose of (14)Csuccimer at 16, 32, or 48 mg/kg, absorption was rapid but variable with peak blood radioactivity levels between one and two hours. On average, 49% of the radiolabeled dose was excreted: 39% in the feces, 9% in the urine and 1% as carbon dioxide from the lungs. Since fecal excretion probably represented nonabsorbed drug, most of the absorbed drug was excreted by the kidneys. The apparent elimination half-life of the radiolabeled material in the blood was about two days.

US Natl Inst Health; DailyMed. Current Medication Information for CHEMET (succimer) capsule (May 2010). Available from, as of June 23, 2010: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?id=18210


In other studies of healthy adult volunteers receiving a single oral dose of 10 mg/kg, the chemical analysis of succimer and its metabolites in the urine showed that succimer was rapidly and extensively metabolized. Approximately 25% of the administered dose was excreted in the urine with the peak blood level and urinary excretion occurring between two and four hours. Of the total amount of drug eliminated in the urine, approximately 90% was eliminated in altered form as mixed succimer-cysteine disulfides; the remaining 10% was eliminated unchanged. The majority of mixed disulfides consisted of succimer in disulfide linkages with two molecules of L-cysteine, the remaining disulfides contained one L-cysteine per succimer molecule.

US Natl Inst Health; DailyMed. Current Medication Information for CHEMET (succimer) capsule (May 2010). Available from, as of June 23, 2010: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?id=18210


The urinary excretion of succimer (meso-2,3-dimercaptosuccinic acid) was studied following oral administration of 10 mg succimer/kg to 6 normal men, aged 22-31 yr. The succimer that was absorbed was extensively biotransformed. After 14 hr only 2.53% of the drug was excreted in the urine as unaltered succimer and 18.1% as altered forms. The unaltered succimer was 12% of the total succimer found in the urine. The altered form(s) of succimer was 88% of the total urinary succimer. The altered succimer can be converted to unaltered succimer by electrolytic reduction, which indicates that the altered forms of succimer are disulfides. The excretion of altered succimer reached a peak between 2 and 4 hr after administration. There were small but significant increases in the excretion of zinc, copper, and lead after succimer. The chelating agent did not influence the urinary excretion of 27 other metals and elements.

PMID:2541962 Aposhian HV et al; Clin Pharmacol Ther 45 (May): 520-6 (1989)


(14)C DMSA was administered to mice iv; the mice were frozen by immersion in dry ice/hexane at 6 and 20 min and 1, 3, 9, and 24 hr after injection. The frozen mice were sectioned and processed for whole-body autoradiography for soluble substances. The radioactivity was highly localized in extracellular fluids such as the sc, intrapleural, ip, and periosteal spaces. There was a pronounced accumulation in the periosteal fluid above that in other fluids during the first hour after injection. Most of the radioactivity was eliminated by the kidney and liver. Pretreatment of a mouse with HgCl2 subcutaneously 1 hr before (14)C DMSA produced an increase in radioactivity in the liver and decrease in lung. A high concentration of radioactivity was seen at the sc site of injection of the HgCl2. The results are interpreted to indicate that most of the DMSA is in the extracellular space but that it can cross cellular membranes to some extent. The pronounced accumulation in periosteal fluid may be an interaction of DMSA with Ca2+ in this space. No tissue had a pronounced retention of the compound, but lung retained more than most other tissues.

PMID:3009254 Lang YY et al; Fundam Appl Toxicol 6 (3): 532-40 (1986)


5.5 Metabolism/Metabolites

Chemical analysis of succimer and its metabolites (primarily mixed disulfides of L-cysteine) in the urine showed that succimer was rapidly and extensively metabolized however the specific site of biotransformation is not known.


/Two/ subjects were given DMSA at 10 mg/kg orally, and urine samples were collected at 1, 2, 4, 6, 9 and 14 hr after administration. Samples were analyzed by HPLC, ion exchange, and TLC techniques. Most of the ingested DMSA was found in the urine in disulfide linkage with L-cysteine. Electrolytic reductive treatment, which breaks disulfide bonds, resulted in the conversion of the mixed disulfides to DMSA and L-cysteine. After the sulfhydryl group was derivatized and the bimane derivatives analyzed by HPLC and fluorescence, a high correlation between the excretion of L-cysteine and DMSA in the urine was evident. Four of the metabolites found in the urine contained L-cysteine and DMSA in different ratios. Results indicated that when DMSA is given orally to humans, it forms mixed disulfides with L-cysteine in preference to the formation of cyclic disulfides of DMSA. L-Cysteine preferentially forms these unique DMSA/mixed disulfides instead of the usual L-cystine. The amount of L-cysteine excreted in the urine as the mixed disulfides far exceeded the amount excreted as L-cystine. This increased excretion of L-cysteine caused by the DMSA exposure implied that a thiol-disulfide exchange between L-cystine and DMSA occurred and/or a direct reaction between L-cysteine and DMSA occurred to form more soluble mixed disulfides.

PMID:2538007 Maiorino RM et al; Toxicol Appl Pharmacol 97 (2): 338-49 (1989)


5.6 Biological Half-Life

48 hours


The apparent elimination half-life of the radiolabeled material in the blood was about two days.

US Natl Inst Health; DailyMed. Current Medication Information for CHEMET (succimer) capsule (May 2010). Available from, as of June 23, 2010: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?id=18210


5.7 Mechanism of Action

Succimer is a heavy metal chelator. It binds with high specificity to ions of lead in the blood to form a water-soluble complex that is subsequently excreted by the kidneys. Succimer can also chelate mercury, cadmium, and arsenic in this manner.


Succimer is a lead chelator; it forms water soluble chelates and, consequently, increases the urinary excretion of lead.

US Natl Inst Health; DailyMed. Current Medication Information for CHEMET (succimer) capsule (May 2010). Available from, as of June 23, 2010: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?id=18210


DMSA chelates by coordination of one sulfur and one oxygen atom with Pb. Solubility of the lead chelates depends on the ionization of the noncoordinated thiol and carboxylic acid groups. Bimane derivatization, HPLC, and fluorescence, as well as gas chromatography can be used for analysis of DMSA in biological fluids. The acid dissociation constants for meso- and racemic-DMSA have been summarized from the literature as have the formation constants of some of the DMSA chelates. DMSA is biotransformed to a mixed disulfide in humans. By 14 hr after DMSA administration (10 mg/kg), only 2.5% of the administered DMSA is excreted in the urine as unaltered DMSA and 18.1% of the dose is found in the urine as altered forms of DMSA. Most altered DMSA in the urine is in the form of a mixed disulfide. It consists of DMSA in disulfide linkages with two molecules of L-cysteine. One molecule of cysteine is attached to each of the sulfur atoms of DMSA. The remaining 10% of the altered DMSA was in the form of cyclic disulfides of DMSA. So far, the mixed disulfide has been found in human but not in rabbit, mouse, or rat urine. Apparently there are species differences in how organisms metabolize meso-DMSA.

PMID:2160791 Aposhian HV, Aposhian MM; Annu Rev Pharmacol Toxicol 30: 279-306 (1990)


API SUPPLIERS

read-more
read-more

01

Sanofi

France

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

arrow
SupplySide West 2024
Not Confirmed
  • fda
  • EDQM
  • WHO-GMP

Virtual BoothSanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.

Flag France
Digital Content Digital Content
USDMF Inactive-api CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
Sanofi Company Banner

02

SIGMA TAU

U.S.A

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

SupplySide West 2024
Not Confirmed
arrow

SIGMA TAU

U.S.A

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

arrow
SupplySide West 2024
Not Confirmed
USDMF Inactive-api CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
blank

03

Helsinn Advanced Synthesis

Switzerland

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

SupplySide West 2024
Not Confirmed
arrow

Helsinn Advanced Synthesis

Switzerland

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

arrow
SupplySide West 2024
Not Confirmed
USDMF Inactive-api CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
blank

04

Country

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

SupplySide West 2024
Not Confirmed
arrow

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

arrow
SupplySide West 2024
Not Confirmed
USDMF Inactive-api CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

API Reference Price

read-more
read-more
[{"dataSource":"API Import","activeIngredients":"","year":"2023","qtr":"Q2","strtotime":1682533800,"product":"MESO-2,3-DIMERCAPTOSUCCINIC ACID","address":"PLOT NO. 40 AND 41, 3RD FLOOR,,VEN TUREAST PLAZA, ROAD NO.2,","city":"FINANCIAL DIST NANAKRAMGUDA,TELANGA","supplier":"HANGZHOU SUNMA TECHNOLOGY CO.,LTD","supplierCountry":"CHINA","foreign_port":"NA","customer":"LAXAI LIFE SCIENCES","customerCountry":"INDIA","quantity":"1.00","actualQuantity":"1","unit":"KGS","unitRateFc":"860","totalValueFC":"872.6","currency":"USD","unitRateINR":"71509","date":"27-Apr-2023","totalValueINR":"71509","totalValueInUsd":"872.6","indian_port":"HYDERABAD AIR","hs_no":"29339990","bill_no":"5709527","productDescription":"API","marketType":"REGULATED MARKET","country":"CHINA","selfForZScoreResived":"Pharma Grade","supplierPort":"NA","supplierAddress":"","customerAddress":"PLOT NO. 40 AND 41, 3RD FLOOR,,VEN TUREAST PLAZA, ROAD NO.2,"}]
27-Apr-2023
27-Apr-2023
KGS
overview
Loading...

Average Price (USD/KGS)

Number of Transactions

Total Quantity (KGS)

Total Value (USD)

Quantity (KGS) & Unit rate (USD/KGS) over time

API Imports and Exports

Importing Country Total Quantity
(KGS)
Average Price
(USD/KGS)
Number of Transactions

Upgrade, download data, analyse, strategize, subscribe with us contact

Related Excipient Companies

Upload your portfolio for free, ask us

Global Sales Information

Do you need Business Intel? Ask us

Market Place

Do you need sourcing support? Ask us

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty